Phanes Therapeutics doses first patient in its Phase 1 study of PT199

By Ayushi Garg  | Date: August 24, 2022

Phanes Therapeutics doses first patient in its Phase 1 study of PT199

Phanes Therapeutics, an established leader in the research of oncology discovery as well as clinical development, has reportedly announced that the first subject has been dosed in phase 1 clinical trial (NCT05431270) of PT199, an mAb or anti-CD73 monoclonal antibody, to treat numerous advanced solid tumors.

PT199 is an anti-CD73 mAb that has a distinct mechanism of action intended to combat the adenosine-mediated immunosuppressive TME or tumor microenvironment. In contrast to several other CD73 inhibitors that only partially inhibit CD73, PT199 completely inhibits both membrane-bound and soluble CD73.

Furthermore, with PT199, no loss of blockage or ‘hook effect’ is seen at greater concentrations. As a result, PT199 overcomes the limitations of existing CD73 inhibitors which are likely to boost antitumor immune activation while potentially providing novel therapy choices for cancer patients.

Dr. Ming Wang, Phanes Therapeutics CEO and Founder remarked that the CD73 pathway is an extremely viable target for tackling the immunosuppressive TME.

Wang added that the firm is thrilled to launch the research and bring this potentially premium mAb to patients suffering from cancer who have limited therapeutic alternatives.

The multi-center Phase I clinical study of PT199 is assessing the tolerability, safety, pharmacodynamics, pharmacokinetics, and preliminary efficiency of PT199, both individually and in tandem with a PD-1 inhibitor, in individuals with metastatic or locally advanced solid tumors that have advanced after every available conventional therapy or for which standard therapy has deemed unsuccessful, unbearable, or is regarded as unsuitable.

As per credible reports, patients aged 18 and above who have a detectable disease with at least one lesion receptive to response evaluation following RECIST 1.1 criteria, sufficient organ function, as well as an ECOG performance status of 0 to 1, are eligible to enroll in the trial.

Source credit:

About Author

Ayushi Garg

Ayushi Garg

Currently working as an associate content writer, Ayushi pens down insightful articles for several websites. She began her profession by taking classes in digital marketing to broaden her skills. Given her passion for writing, she took up several freelancing projects ...

Read More